ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/gastric-and-oesophageal/advanced-metastatic
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gastrointestinal (Upper) / Gastric and oesophageal - Advanced/metastatic
30
trial(s) found.
NCT07670312
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1b/2, Multicenter, Non-randomized, Open-label, Multiple Dose First- In-Human Study of XYA02 in Patients With Advanced Solid Tumors (
XYA02-100
)
anti-MUC1 antibody-drug conjugate
Colorectal cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Solid tumour
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT07546812
Advanced
Phase 2
Recruiting
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas (
GS-US-742-7757
)
anti-CCR8 monoclonal antibody
anti-PD-1 monoclonal antibody
Gastric adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
cytotoxic chemotherapy
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Hollywood Private Hospital
NCT07431281
Advanced
Phase 3
Recruiting
A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02) (
D9803C00001
)
anti-CLDN18.2 antibody-drug conjugate
bispecific PD-1/TIGIT antibody
fluoropyrimidine
Gastric cancer
Gastroesophageal junction adenocarcinoma
Oesophageal cancer
NSW
2031 - Randwick - Prince of Wales Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (WITHDRAWN)
ACT
2605 - Garran - The Canberra Hospital (WITHDRAWN)
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07341737
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicentre, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of SL-28 in Patients With Advanced Solid Tumours (
SL-28-FIH
)
allogeneic cell therapy,unspecified mechanism
Bladder cancer
Breast cancer
Cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Hepatocellular carcinoma
Kidney cancer
Lung adenocarcinoma
Lung cancer
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin cancer
NSW
2170 - Liverpool - Liverpool Hospital
QLD
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT07262619
Advanced
Phase 1 / Phase 2
Recruiting
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naïve Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors (
EIK1005-002
)
WRN inhibitor
anti-PD-1 monoclonal antibody
Cancer
Endometrial cancer
Gastric cancer
Microsatellite instability high solid tumour
Mismatch repair deficient colorectal cancer
Solid tumour
dMMR solid cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - GenesisCare North Shore Private Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
3199 - Frankston - PASO Medical
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NCT07221149
Advanced
Phase 2 / Phase 3
Recruiting
ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (
CA266-0004
)
anti-PD-1 monoclonal antibody
bispecific PD-L1/VEGFA antibody
Gastric cancer
Gastroesophageal junction adenocarcinoma
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3084 - Heidelberg - Warringal Private Hospital
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
SA
5112 - Elizabeth Vale - Lyell McEwin Hospital
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT07115043
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6750, a CD8 Guided IL-2 Agent Alone and in Combination With Other Anti-cancer Agents in Participants With Select Advanced or Metastatic Solid Tumors (
D7350C00001
)
CD8-guided IL-2 candidate
Gastric cancer
VIC
3002 - East Melbourne - Epworth Freemasons
NCT07070232
Advanced
Phase 1 / Phase 2
Recruiting
A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors (
BNT326-01
)
anti-ERBB3 antibody-drug conjugate
Breast cancer
Cervical cancer
Colorectal adenocarcinoma
Gastroesophageal junction adenocarcinoma
Melanoma
Mucosal melanoma
Non-small cell lung cancer
Solid tumour
Uveal melanoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Cancer Research SA
WA
6009 - Nedlands - One Clinical Research
NCT06974110
Advanced
Phase 1
Recruiting
A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors (
MOMA-341-001
)
WRN inhibitor
Cancer
Colorectal cancer
Endometrial cancer
Gastric cancer
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital (COMPLETED)
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06921837
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, First-in-Human, Dose Escalation and Expansion Study of BDC-4182 as a Single Agent in Patients With Advanced Gastric and Gastroesophageal Cancer (
BBI-4182-101
)
anti-CLDN18.2 immune-stimulating antibody conjugate,TLR7/8 agonist
Gastric cancer
Gastroesophageal junction adenocarcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4575 - Birtinya - Sunshine Coast University Hospital
NCT06910657
Advanced
Phase 1
Recruiting
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors (
VM-002-101
)
oncolytic virus,undisclosed mechanism
Bladder cancer
Breast cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Head and neck cancer
Hepatocellular carcinoma
Lung cancer
Melanoma
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Sarcoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06901531
Advanced
Phase 3
Recruiting
A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination With Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors Are HER2-negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-Positive (
LUCERNA
)
anti-CLDN18.2 monoclonal antibody
anti-PD-1 monoclonal antibody
Gastroesophageal junction adenocarcinoma
NSW
2217 - Kogarah - St George Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - The Prince Charles Hospital
NCT06789172
Advanced
Phase 1
Recruiting
A Phase 1, Open-label, Multicenter, Dose-escalation and Cohort Expansion Study of OKN4395, a Triple Antagonist of EP2, EP4, and DP1 Prostanoid Receptors, as Monotherapy and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors (
INVOKE
)
anti-PD-1 monoclonal antibody
prostaglandin EP2/EP4/DP1 receptor inhibitor
Adenocarcinoma
Colorectal cancer
Dedifferentiated liposarcoma
Fibrosarcoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Leiomyosarcoma
Non-small cell lung cancer
Sarcoma
Solid tumour
Solitary fibrous tumour
Undifferentiated pleomorphic sarcoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
WA
6009 - Nedlands - Linear Clinical Research
NCT06764875
Advanced
Phase 3
Recruiting
A Randomized, Phase â…¢ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01) (
D702AC00001
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
bispecific PD-1/TIGIT antibody
Gastric cancer
Gastroesophageal junction adenocarcinoma
HER2-positive gastric cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06731478
Advanced
Phase 3
Recruiting
A Multicenter, Randomized, Open-Label, Phase 3 Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab Versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab as First-Line Treatment in Participants With Unresectable, Locally Advanced or Metastatic HER2-Positive Gastric Or Gastroesophageal Junction (GEJ) Cancer (Destiny-Gastric05) (
DS8201-724
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
Gastric cancer
Gastroesophageal cancer
Gastroesophageal junction adenocarcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2500 - Wollongong - Wollongong Hospital
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3168 - Clayton - Monash Medical Centre
QLD
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06581432
Advanced
Phase 2
Recruiting
Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2-mutated or Overexpressed/Amplified Solid Tumours (
1479-0009
)
ERBB2 inhibitor,second generation
Cervical cancer
Gastroesophageal junction adenocarcinoma
NOT Breast cancer
NOT Colorectal adenocarcinoma
NOT Gastroesophageal cancer
NOT Gastroesophageal junction adenocarcinoma
NOT Pancreatic adenocarcinoma
NOT Pancreatic cancer
NOT Squamous non-small-cell lung cancer
Non-small cell lung cancer
Solid tumour
Urothelial carcinoma
NSW
2065 - St Leonards - GenesisCare North Shore Private Hospital
2109 - North Ryde - Macquarie University Hospital
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital
NCT06535607
Advanced
Phase 2
Recruiting
A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors (
eVOLVE-02
)
bispecific PD-L1/CTLA4 antibody
Cervical cancer
Head and neck squamous cell carcinoma
Mesothelioma
Oesophageal squamous cell carcinoma
Pleural mesothelioma
VIC
3168 - Clayton - Monash Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
NCT06532006
Advanced
Phase 3
Recruiting
A Randomized, Double-blinded, Multicenter, Phase â…¢ Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Trastuzumab and Chemotherapy (XELOX) With or Without Pembrolizumab for the First Line Treatment of Locally Advanced or Metastatic Gastroesophageal Junction and Gastric Cancer (
HLX22-GC-301
)
anti-ERBB2 monoclonal antibody
anti-PD-1 monoclonal antibody
Gastric cancer
Gastroesophageal junction adenocarcinoma
HER2-positive gastric cancer
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2560 - Campbelltown - GenesisCare Campbelltown
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3199 - Frankston - Peninsula Health Frankston Hospital
QLD
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT06465069
Advanced
Phase 1
Recruiting
A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors (
NEXUS-01
)
anti-NECTIN4 antibody-drug conjugate
Bladder cancer
Cervical cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal pelvis cancer
Solid tumour
Triple-negative breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Bladder cancer
Breast cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Platinum resistant ovarian cancer
Prostate adenocarcinoma
Sarcoma
Small-cell lung cancer
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06219941
Advanced
Phase 2
Recruiting
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01) (
D9800C00001
)
anti-CLDN18.2 antibody-drug conjugate
Biliary tract cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
NSW
2031 - Randwick - Prince of Wales Hospital
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06172478
Advanced
Phase 2
Recruiting
HERTHENA-PanTumor01 (
U31402-277
): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
anti-ERBB3 antibody-drug conjugate
Bladder cancer
Cervical cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
High-grade serous ovarian cancer
Melanoma
Oesophageal cancer
Pancreatic adenocarcinoma
Prostate adenocarcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3168 - Clayton - Monash Medical Centre
QLD
4032 - Chermside - Icon Cancer Care Chermside
4812 - Hyde Park - Icon Cancer Centre Townsville
TAS
7000 - Hobart - ICON Cancer Care Hobart
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05872295
Advanced
Phase 1
Recruiting
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors (
IKS014-01
)
anti-ERBB2 antibody-drug conjugate,MMAF-payload
Breast cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Solid tumour
NSW
2109 - North Ryde - Macquarie University Hospital
2139 - Concord - Concord Repatriation General Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
3199 - Frankston - Peninsula Health Frankston Hospital
WA
6009 - Nedlands - Linear Clinical Research
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05636215
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Multicenter, Open-label Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors (
CIBI354A101
)
anti-ERBB2 antibody-drug conjugate,topoisomerase inhibitor 1-payload
Biliary tract cancer
Breast cancer
Colorectal cancer
Gastric cancer
Gynaecological cancer
Solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd (COMPLETED)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (COMPLETED)
VIC
3168 - Clayton - Monash Medical Centre (COMPLETED)
QLD
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (COMPLETED)
NCT05086692
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors (
ABILITY-1
)
IL-2 superkine
Acral lentiginous melanoma
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial cancer
Endometrial carcinoma
Epithelial Ovarian Cancer
Fallopian tube cancer
Gastric cancer
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Merkel cell carcinoma
Mucosal melanoma
Non-melanoma skin cancer
Non-squamous non-small-cell lung cancer
Oesophageal cancer
Ovarian cancer
Pancreatic adenocarcinoma
Pleural mesothelioma
Primary peritoneal serous carcinoma
Skin cancer
Solid tumour
Squamous non-small-cell lung cancer
Triple-negative breast cancer
dMMR solid cancer
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
QLD
4120 - Greenslopes - Greenslopes Private Hospital
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic
NCT04895709
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (
CA052-002
)
anti-CCR8 monoclonal antibody
Cervical cancer
Clear cell renal cell carcinoma
Gastroesophageal junction adenocarcinoma
Head and neck squamous cell carcinoma
Melanoma
Microsatellite stable colorectal cancer
Non-small cell lung cancer
Ovarian cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre
2170 - Liverpool - Liverpool Hospital
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
WA
6009 - Nedlands - One Clinical Research
NCT03175224
Advanced
Phase 2
Recruiting
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (
SPARTA
)
MET inhibitor,type 1
Cancer
Central nervous system cancer
Colon adenocarcinoma
Gastric cancer
Gastroesophageal junction adenocarcinoma
Glioblastoma
Kidney cancer
Lung cancer
MET:alteration
MET:fusion
Non-small cell lung cancer
Pancreatic cancer
Solid tumour
Thyroid cancer
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
ACTRN12605000454673
Advanced
Phase 2
Recruiting
Does the use of nizatidine (Tazac) as a prokinetic agent improve gastric emptying in patients who have had an oesophagectomy for oesophageal cancer? (
Study-Number-07-09-08-04
)
histamine H2 receptor antagonist
Oesophageal adenocarcinoma
NCT05642949
Advanced
Phase 1 / Phase 2
Unknown
Phase 1/2, Multi-center, Open-label, Dose Escalation and Cohort Expansion Study to Evaluate the Safety/Tolerability, Pharmacokinetics and Efficacy of MHB036C in Participants With Advanced or Metastatic Solid Tumors (
MHB036C-CP001EN
)
anti-Trop2 antibody-drug conjugate
Breast cancer
Endometrial cancer
Gastric cancer
Head and neck squamous cell carcinoma
Non-small cell lung cancer
Oesophageal squamous cell carcinoma
Ovarian cancer
Pancreatic adenocarcinoma
Prostate cancer
Small-cell lung cancer
Solid tumour
Sweat gland carcinoma
Urothelial carcinoma
VIC
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital
QLD
4217 - Benowa - Pindara Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (29)
Unknown (1)
Recruitment Country and State
NSW (23)
VIC (22)
QLD (16)
WA (15)
SA (9)
NZ (2)
TAS (1)
Phase
Phase 1 (7)
Phase 1 / Phase 2 (10)
Phase 2 (7)
Phase 2 / Phase 3 (1)
Phase 3 (5)
Trial Type
Advanced (30)
Cancer Therapy Class
PD-1/PD-L1
50%
PD-1
43%
ERBB2
20%
CLDN18.2
13%
PD-L1
13%
TIGIT
10%
VEGFA
10%
CCR8
7%
WRN
7%
ERBB3
7%
SMO
7%
MET
7%
MUC1
3%
VEGFR2
3%
prostaglandin DP1 receptor
3%
prostaglandin EP2
3%
prostaglandin EP2 receptor
3%
prostaglandin EP4 receptor
3%
CTLA4
3%
Nectin4
3%
B7H3
3%
VEGF
3%
IL-2
3%
Trop2
3%
Facility
3168 - Clayton - Monash Medical Centre (9)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (8)
2050 - Camperdown - Chris O'Brien Lifehouse (6)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (6)
6009 - Nedlands - Linear Clinical Research (5)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (5)
4102 - Woolloongabba - Princess Alexandra Hospital (4)
6150 - Murdoch - Fiona Stanley Hospital (4)
3065 - Fitzroy - St Vincent's Hospital Melbourne (4)
2109 - North Ryde - Macquarie University Hospital (4)
2170 - Liverpool - Liverpool Hospital (3)
2065 - St Leonards - GenesisCare North Shore Private Hospital (3)
3004 - Melbourne, Southbank - Alfred Health (3)
3199 - Frankston - Peninsula Health Frankston Hospital (3)
2031 - Randwick - Scientia Clinical Research Ltd (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (2)
5042 - Bedford Park - Flinders Medical Centre (2)
2031 - Randwick - Prince of Wales Hospital (2)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (2)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (2)
4575 - Birtinya - Sunshine Coast University Hospital (2)
2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (2)
6009 - Nedlands - One Clinical Research (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (2)
6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (2)
2139 - Concord - Concord Repatriation General Hospital (2)
4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
6009 - Nedlands - Hollywood Private Hospital (1)
2605 - Garran - The Canberra Hospital (1)
4224 - Tugun - Genesis Care Tugun - John Flynn Private Hospital (1)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
3199 - Frankston - PASO Medical (1)
3350 - Ballarat - Grampians Health Service's Ballarat Base Hospital (1)
NZ.4442 - Roslyn - Palmerston North Hospital Cancer Centre - Palmerston North Hospital (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
3084 - Heidelberg - Warringal Private Hospital (1)
5112 - Elizabeth Vale - Lyell McEwin Hospital (1)
3002 - East Melbourne - Epworth Freemasons (1)
2065 - Wollstonecraft - Melanoma Institute Australia - The Poche Centre (1)
4215 - Southport - Tasman Oncology (1)
5000 - Adelaide - Cancer Research SA (1)
2217 - Kogarah - St George Hospital (1)
4032 - Chermside - The Prince Charles Hospital (1)
2500 - Wollongong - Wollongong Hospital (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2560 - Campbelltown - GenesisCare Campbelltown (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
4032 - Chermside - Icon Cancer Care Chermside (1)
4812 - Hyde Park - Icon Cancer Centre Townsville (1)
7000 - Hobart - ICON Cancer Care Hobart (1)
4575 - Sunshine Coast - Sunshine Coast University Private Hospital (1)
4120 - Greenslopes - Greenslopes Private Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
3144 - Malvern - GenesisCare Cabrini, Cabrini Hospital (1)
4217 - Benowa - Pindara Private Hospital (1)
Cancer Type
Cancer
Gastroesophageal cancer
Gastrointestinal cancer
Solid tumour
Upper gastrointestinal cancer
Gastric cancer
Oesophageal cancer
Thoracic cancer
Gastric carcinoma
Gastroesophageal junction adenocarcinoma
Gynaecological cancer
Pancreatobiliary cancer
Colorectal cancer
Lower gastrointestinal cancer
Lung cancer
Respiratory tract cancer
Non-small cell lung cancer
Pancreatic cancer
Breast cancer
Ovarian cancer
Urogenital cancer
Head and neck cancer
Cervical cancer
HPV-related cancer
HPV16-positive cancer
Viral-related cancer
Head and neck squamous cell carcinoma
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Endometrial cancer
Melanoma
Bladder cancer
Hepatobiliary cancer
Kidney cancer
Male genital cancers
Prostate cancer
Hepatocellular carcinoma
Colorectal adenocarcinoma
Clear cell renal cell carcinoma
Carcinoma
Breast adenocarcinoma
Triple-negative breast cancer
Epithelial Ovarian Cancer
Gastric adenocarcinoma
Skin cancer
Sarcoma
Urothelial carcinoma
Oesophageal squamous cell carcinoma
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Neuroendocrine carcinoma
Biliary tract cancer
Non-squamous non-small-cell lung cancer
Biomarker-defined solid tumour
MSI-H/dMMR solid tumour
dMMR solid cancer
Mucosal melanoma
HER2-positive gastric cancer
Mesothelioma
Pleural mesothelioma
High-grade serous ovarian cancer
Ovarian adenocarcinoma
Ovarian serous carcinoma
Prostate adenocarcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Non-melanoma skin cancer
cytotoxic chemotherapy
Lung adenocarcinoma
Microsatellite instability high solid tumour
Mismatch repair deficient colorectal cancer
Uveal melanoma
Adenocarcinoma
Dedifferentiated liposarcoma
Fibrosarcoma
Leiomyosarcoma
Liposarcoma
Soft tissue sarcoma
Solitary fibrous tumour
Undifferentiated pleomorphic sarcoma
Renal pelvis cancer
Castrate-resistant prostate cancer
Platinum resistant ovarian cancer
Acral lentiginous melanoma
Cutaneous basal cell carcinoma
Cutaneous melanoma
Cutaneous squamous cell carcinoma
Endometrial carcinoma
Fallopian tube cancer
Merkel cell carcinoma
Peritoneal cancer
Primary peritoneal serous carcinoma
Squamous non-small-cell lung cancer
Microsatellite stable colorectal cancer
Non-microsatellite instability-high colorectal cancer
Central nervous system cancer
Colon adenocarcinoma
Endocrine gland cancer
Glioblastoma
Glioma
High-grade glioma
MET:alteration
MET:fusion
Malignant glioma
Neurological cancer
Thyroid cancer
Oesophageal adenocarcinoma
Sweat gland carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy